Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ORGO Organogenesis	$4.70 -4.3%	$4.13	$2.45 ▼ $6.71	$622.87M	1.76	767,381 shs	472,993 shs
RVNC Revance Therapeutics	$3.65	$3.65	$2.76 ▼ $6.65	$381.02M	0.9	3.78 million shs	N/A
TKNO Alpha Teknova	$4.80 -1.6%	$4.98	$3.75 ▼ $10.37	$261.15M	0.32	329,235 shs	390,208 shs
ZOM Zomedica		$0.12	$0.09 ▼ $0.16	$95.35M	1.03	4.72 million shs	790,936 shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ORGO Organogenesis	+0.41%	+9.11%	+9.35%	+62.05%	+84.59%
RVNC Revance Therapeutics	0.00%	0.00%	0.00%	0.00%	-44.61%
TKNO Alpha Teknova	+2.09%	+12.18%	+8.69%	-25.04%	+22.92%
ZOM Zomedica	0.00%	0.00%	0.00%	0.00%	-34.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ORGO Organogenesis	4.2165 of 5 stars	3.3	1.0	0.0	4.3	2.3	4.2	0.6
RVNC Revance Therapeutics	1.6914 of 5 stars	2.0	0.0	0.0	4.7	0.0	1.7	0.6
TKNO Alpha Teknova	2.4379 of 5 stars	3.8	1.0	0.0	0.0	2.6	1.7	0.6
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ORGO Organogenesis	2.67	Moderate Buy	$7.50	59.57% Upside
RVNC Revance Therapeutics	2.00	Hold	$4.23	15.98% Upside
TKNO Alpha Teknova	3.50	Strong Buy	$10.00	108.33% Upside
ZOM Zomedica	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZOM, RVNC, ORGO, and TKNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	ORGO Organogenesis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$7.00 ➝ $9.00
7/22/2025	TKNO Alpha Teknova	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
7/15/2025	ORGO Organogenesis	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/15/2025	ORGO Organogenesis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$7.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ORGO Organogenesis	$482.04M	1.24	$0.20 per share	23.53	$1.84 per share	2.55
RVNC Revance Therapeutics	$234.04M	1.63	N/A	N/A	($1.73) per share	-2.11
TKNO Alpha Teknova	$37.74M	6.81	N/A	N/A	$1.42 per share	3.38
ZOM Zomedica	$25.19M	0.00	N/A	N/A	$0.24 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ORGO Organogenesis	$860K	-$0.14	N/A	N/A	N/A	-1.92%	-0.37%	-0.20%	N/A
RVNC Revance Therapeutics	-$323.99M	-$1.93	N/A	N/A	N/A	-74.67%	N/A	-37.22%	N/A
TKNO Alpha Teknova	-$26.75M	-$0.42	N/A	N/A	N/A	-55.24%	-26.51%	-18.40%	N/A
ZOM Zomedica	-$34.53M	-$0.06	N/A	N/A	N/A	-232.88%	-12.47%	-11.84%	N/A

Latest ZOM, RVNC, ORGO, and TKNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	ORGO Organogenesis	-$0.01	-$0.09	-$0.08	-$0.10	$104.75 million	$101.01 million
8/7/2025	Q2 2025	TKNO Alpha Teknova	-$0.1004	-$0.07	+$0.0304	-$0.07	$9.90 million	$10.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ORGO Organogenesis	N/A	N/A	N/A	N/A	N/A
RVNC Revance Therapeutics	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A
ZOM Zomedica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ORGO Organogenesis	N/A	3.95	3.45
RVNC Revance Therapeutics	N/A	4.12	3.05
TKNO Alpha Teknova	0.17	5.87	4.71
ZOM Zomedica	N/A	10.82	10.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ORGO Organogenesis	49.57%
RVNC Revance Therapeutics	97.70%
TKNO Alpha Teknova	13.81%
ZOM Zomedica	8.95%

Insider Ownership

Company	Insider Ownership
ORGO Organogenesis	33.00%
RVNC Revance Therapeutics	5.10%
TKNO Alpha Teknova	12.50%
ZOM Zomedica	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ORGO Organogenesis	950	126.86 million	85.00 million	Optionable
RVNC Revance Therapeutics	500	104.39 million	99.07 million	Optionable
TKNO Alpha Teknova	240	53.51 million	46.83 million	Not Optionable
ZOM Zomedica	50	979.95 million	938.89 million	Not Optionable

ZOM, RVNC, ORGO, and TKNO Headlines

Recent News About These Companies

Zomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on the VETIGEL Hemostatic Product - The Future of Rapid Bleeding Control in Veterinary Medicine

August 12 at 4:49 PM | finanznachrichten.de

Zomedica Achieves Record Revenue Growth in Q2 2025

August 6, 2025 | msn.com

Non-Pharmacologic Solutions for Pet Dental Health From Prevention to Recovery

July 11, 2025 | dvm360.comD

Zomedica Corp.: Zomedica Announces Strategic PulseVet Shock Wave Partnership with World Equestrian Center - Ocala

July 10, 2025 | finanznachrichten.de

Zomedica Announces Issuance of Additional Patent for its TRUVIEW (R) Microscope - Morningstar

June 25, 2025 | morningstar.comM

Zomedica Corp.: Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations

May 20, 2025 | finanznachrichten.de

Treat pet pain, inflammation, and anxiety with this high-tech at home therapy

April 24, 2025 | click2houston.comC

Helping Pets Live Pain-Free: High-Tech Treatments for Our Four-Legged Family Members

April 11, 2025 | pix11.comP

Is Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March?

March 28, 2025 | insidermonkey.com

15 Cheapest Stocks Insiders Are Buying In March

March 27, 2025 | insidermonkey.com

Earnings call transcript: Zomedica Q4 2024 shows revenue growth

March 15, 2025 | investing.com

Q4 2024 Zomedica Corp Earnings Call

March 15, 2025 | finance.yahoo.com

Zomedica Corp. (ZOMDF) Q4 2024 Earnings Call Transcript

March 13, 2025 | seekingalpha.com

Zomedica (ZOMDF) Gets a Buy from Noble Financial

March 11, 2025 | markets.businessinsider.com

Zomedica Corp.

March 8, 2025 | wsj.com

Zomedica Corp. Announces Transition to OTCQB Venture Market

March 4, 2025 | accessnewswire.comA

NYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)

March 4, 2025 | businesswire.com

Zomedica to Report Fourth Quarter and Full Year 2024 Financial Results with a Business Update on March 13th at 4:30 p.m. ET

February 26, 2025 | accessnewswire.comA

Zomedica Corp.: Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

February 12, 2025 | finanznachrichten.de

Zomedica Improves Efficiency and Cuts Costs by Moving to New Headquarters

February 12, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZOM, RVNC, ORGO, and TKNO Company Descriptions

Organogenesis NASDAQ:ORGO

$4.70 -0.21 (-4.28%)

Closing price 04:00 PM Eastern

Extended Trading

$4.74 +0.04 (+0.96%)

As of 07:25 PM Eastern

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Revance Therapeutics NASDAQ:RVNC

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Alpha Teknova NASDAQ:TKNO

$4.80 -0.08 (-1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$4.80 0.00 (0.00%)

As of 04:10 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Zomedica NYSEAMERICAN:ZOM

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time